Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- Vanda Pharmaceuticals
- Study ID
- NCT03154697
- Status
- Recruiting
Conditions
- Sleep Disturbances in Smith-Magenis Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 3 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Data collection of sleep disturbances in individuals with SMS — OTHERData related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
Study Details
This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.
Key Dates
- Start date
- Jan 31, 2016
- Status verified
- Oct 2018
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 1,000 participants (estimated)
Primary Outcome Measure
Number of individuals with Smith- Magenis syndrome [ Time Frame: 5 years ]
Central Contacts
- Vanda Pharmaceuticals202-734-3400
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vanda Pharmaceuticals | Washington D.C. | District of Columbia | 20037 | Vanda Pharmaceuticals 202-734-3400 |
Find similar trials in Washington D.C., DC
By research site